Current management of cervical cancer in Poland-Analysis of the questionnaire trial for the years 2002-2014 in relation to ASCO 2016 recommendations.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
13
06
2018
accepted:
13
12
2018
entrez:
1
2
2019
pubmed:
1
2
2019
medline:
24
9
2019
Statut:
epublish
Résumé
To assess the survival of patients with cervical cancer (CC). Since the recommendations concerning cervical cancer management adopted by Polish medical societies do not differ significantly from the ESGO or non-European guidelines, and the fact that evaluation of the system for CC treatment in Poland, as well as the mortality rate of Polish women with CC, which is 70% higher than the average for European Union (EU) countries, justifies the hypothesis that treatment of CC in Poland deviates from the Polish and international recommendations. This article puts forward the current management of cervical cancer in Poland and discusses it in the context of ASCO guidelines. A survey retrospective multicenter analysis of the medical records of 1247 patients with cervical cancer who underwent treatment for disease and who had completed at least two years of follow-up. Although concurrent radiotherapy and chemotherapy is a standard treatment of FIGO IB to IVA cervical cancer patients in enhanced- and maximum-resources settings, in our analysis, we found that the percentage of women subjected to chemotherapy was lower than in countries where total survival rates were lower. Within the IA to II A cervical cancer patients studied group, the methods of treatment remained in line with ASCO guidelines for countries with the highest standard of care. Although concurrent radiotherapy and chemotherapy is a standard treatment of FIGO IB to IVA cervical cancer patients in enhanced- and maximum-resources settings, in our analysis, we found that the percentage of women subjected to chemotherapy was lower than in countries where total survival rates were lower. Our findings, together with the inconsistencies within the cervical cancer screening program, may be one of the explanations of poorer survival rate of women with cervical cancer in Poland.
Identifiants
pubmed: 30703105
doi: 10.1371/journal.pone.0209901
pii: PONE-D-18-11024
pmc: PMC6354992
doi:
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0209901Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Obstet Gynecol. 2002 May;99(5 Pt 1):855-67
pubmed: 11978302
N Engl J Med. 1999 Apr 15;340(15):1144-53
pubmed: 10202165
J Clin Oncol. 2008 Dec 10;26(35):5802-12
pubmed: 19001332
J Am Coll Radiol. 2012 Jun;9(6):395-402
pubmed: 22632665
J Clin Oncol. 2002 Feb 15;20(4):966-72
pubmed: 11844818
Int J Gynaecol Obstet. 2016 Sep;134(3):239-46
pubmed: 27350227
J Clin Oncol. 2002 Feb 15;20(4):891-3
pubmed: 11844807
Ginekol Pol. 2015 Sep;86(9):712-4
pubmed: 26665575
Ann Oncol. 2017 Jul 1;28(suppl_4):iv72-iv83
pubmed: 28881916
Asia Pac J Clin Oncol. 2013 Dec;9(4):349-56
pubmed: 23710586
Gynecol Oncol. 2000 Aug;78(2):187-93
pubmed: 10926801
J Natl Compr Canc Netw. 2015 Apr;13(4):395-404; quiz 404
pubmed: 25870376
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Ginekol Pol. 2016;87(9):670-6
pubmed: 27723078
J Clin Oncol. 2016 Sep 20;34(27):3354-5
pubmed: 27382101
Int J Gynaecol Obstet. 2012 Oct;119 Suppl 2:S100-9
pubmed: 22999501
Eur J Epidemiol. 2017 Jun;32(6):529-532
pubmed: 28780640
Eur J Obstet Gynecol Reprod Biol. 2009 Nov;147(1):78-82
pubmed: 19713027
J Clin Oncol. 2007 Jun 10;25(17):2383-8
pubmed: 17557951
J Clin Oncol. 2000 Apr;18(8):1606-13
pubmed: 10764420
N Engl J Med. 1999 Apr 15;340(15):1154-61
pubmed: 10202166
Am J Clin Oncol. 2012 Aug;35(4):399-405
pubmed: 22810416
N Engl J Med. 1999 Apr 15;340(15):1137-43
pubmed: 10202164
Front Oncol. 2016 Jun 28;6:160
pubmed: 27446806
Int J Gynaecol Obstet. 2009 May;105(2):107-8
pubmed: 19342051
Lancet Oncol. 2014 Jan;15(1):23-34
pubmed: 24314615
J Clin Oncol. 2014 Feb 20;32(6):542-7
pubmed: 24449243
N Engl J Med. 1999 Apr 15;340(15):1198-200
pubmed: 10202172
Cochrane Database Syst Rev. 2015 Apr 07;(4):CD010260
pubmed: 25847525
Ginekol Pol. 2018;89(2):68-73
pubmed: 29512810
Int J Clin Oncol. 2015 Apr;20(2):240-8
pubmed: 25800808